Prevention · Screening · Early detection
Colorectal Cancer Screening
Bowel screening can detect cancer early and identify precancerous polyps. The test is only useful if recommended follow-up is completed.
Chapter 10 of 16
Choose a chapter
Key facts
- Many international guidelines start average-risk screening at 45.
- Positive stool screening generally needs colonoscopy.
- Family history, polyps and inherited syndromes change the schedule.
Recommendations at a glance
These are guideline comparisons, not a personalised prescription. Symptoms and high-risk history take priority over routine screening schedules.
| Guideline / group | Age or eligibility | Test / interval | Important limitation |
|---|---|---|---|
| USPSTF average risk | 45–75 | FIT yearly OR normal high-quality colonoscopy every 10 years | Positive stool test needs colonoscopy |
| USPSTF older adults | 76–85 | Select individually | Health, prior screening and preferences matter |
| Family history / polyps / IBD / inherited syndrome | Earlier or more frequent as indicated | Specialist surveillance | Do not apply average-risk intervals |
Choose the right next step
- New or concerning symptoms? Arrange diagnostic assessment. Severe bleeding, breathlessness or new neurological weakness needs urgent care.
- No symptoms, but previous cancer, precancer or increased inherited risk? Ask for an individual surveillance plan; average-risk intervals may not apply.
- No such history? Use this chapter to discuss prevention and, where appropriate, age- and test-specific screening. Lifestyle exposures alone do not establish eligibility for every test.
- After testing: Collect the result, complete any referral, and record the next review date. A normal screen does not explain a later symptom.
Why screening can prevent some bowel cancers
Some colorectal cancers develop through an adenoma-to-cancer sequence over years. Finding and removing relevant polyps can interrupt this process, though not every polyp progresses and not every cancer follows the same pathway. Age, family history, inflammatory bowel disease, tobacco, alcohol and obesity can influence risk.
Stool tests
FIT detects human blood in stool and is commonly repeated yearly in USPSTF-based schedules. High-sensitivity guaiac testing is another annual option. Validated stool DNA-FIT tests are used at longer, test-specific intervals; USPSTF lists one to three years. These are repeated screening strategies, not one-time guarantees. A positive result should lead to colonoscopy rather than another stool test intended to cancel the first result.
Visual examinations
Colonoscopy examines the colon and permits polyp removal, usually every ten years after a high-quality normal average-risk examination. CT colonography is commonly every five years; an abnormality may still require colonoscopy. Flexible sigmoidoscopy examines only the lower colon and may be used every five years or at longer intervals combined with annual FIT. Bowel preparation, sedation where used, bleeding and perforation risks must be discussed.
Starting and stopping
USPSTF recommends screening at 45–49 (grade B) and 50–75 (grade A). At 76–85, the decision is selective (grade C) based on health, preferences and prior screening; screening is generally discontinued after 85. These are US recommendations. India does not have an equivalent universal national colorectal-screening programme; discuss local resources and individual risk.
Family history and hereditary syndromes
Under ACG 2021, colorectal cancer or an advanced polyp in one first-degree relative before 60, or at least two first-degree relatives at any age, generally leads to colonoscopy from 40 or ten years before the youngest diagnosis, whichever is earlier, repeated every five years. With one affected first-degree relative at 60 or older, screening begins at 40 and then follows average-risk intervals. Confirm the relative’s diagnosis and the applicable local plan. Lynch syndrome needs gene-specific colonoscopic surveillance, commonly beginning in early adulthood. FAP can require surveillance in childhood or adolescence and risk-reducing surgery. These schedules should be set by a genetics or gastroenterology service, not the average-risk tool.
New tests, symptoms and access
ACS 2026 includes blood-based screening only as a non-preferred option for people unwilling to use stool or visual tests; limited precancer detection is a concern, and a positive result requires colonoscopy. This is not a universal multicancer blood-test recommendation. Rectal bleeding, iron-deficiency anaemia, persistent bowel change or unexplained weight loss need diagnostic evaluation, even below screening age or after a negative FIT.
Practical steps
- Choose a test you can repeat and a service that can arrange colonoscopy if needed.
- Bring polyp histology, bowel-preparation quality and family history records.
- Do not repeat a positive FIT to avoid colonoscopy.
Myth and fact
A negative stool test rules out the cause of visible bleeding.
False. Symptomatic bleeding needs its own clinical assessment.
Frequently asked questions
Is colonoscopy needed after a positive FIT?
Generally yes, if clinically appropriate; the stool result does not identify the cause of bleeding.
Can I use a ten-year interval after polyps?
Not automatically. Number, size, histology, removal completeness and examination quality determine surveillance.
Continue learning
Sources and guideline context
- USPSTF — Colorectal cancer screening
18 May 2021; A/B/C by age
- ACS — Colorectal screening options
Current ACS recommendations, accessed 18 October 2026; blood tests not preferred
- ACG — Colorectal screening recommendations
2021 recommendations summarized on current ACG patient page
- NCI — Genetic testing for inherited cancer risk
Living resource